Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

In this case report, a young male developed bilateral pleural effusion and persistent fever after starting divalproex sodium for bipolar disorder, which improved upon discontinuation of the drug, suggesting a possible link between divalproex sodium and pleural effusion.

This narrative review suggests that the association between weight-loss medications and telogen effluvium is primarily due to metabolic changes from rapid weight loss, rather than a direct pharmacological effect on hair follicles.

This study demonstrated that the pharmacokinetic profiles of finasteride and doxazosin remain bioequivalent when administered in combination compared to when each drug is taken alone.

This case report details a fixed-drug eruption in a woman linked to the use of dextromethorphan, marking it as a previously unreported skin reaction to this medication.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study found that adding fexofenadine to DPCP treatment in non-atopic Alopecia areata patients did not significantly improve hair regrowth, but it did significantly reduce treatment-related discomfort.

This study found that finasteride use is associated with both known and new adverse events, which vary by gender and age, as well as some events not previously listed in the drug insert.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This study concluded that Flaxin tablets and the reference formulation are bioequivalent in terms of absorption rate and extent when administered as a single 5 mg dose to healthy male volunteers.

This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.

This systematic review of three randomized controlled trials found that topical eflornithine is an effective adjunctive therapy for reducing unwanted facial hair in women with hirsutism, with benefits lasting at least six months, although efficacy may diminish over time.

Finasteride may help reduce symptoms in male Tourette syndrome patients.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

This update provides information on new drug approvals but does not offer new clinical research findings.

This study concluded that two exemestane preparations are bioequivalent, using a high-performance liquid chromatographic mass spectrometric method to measure concentrations in human plasma.

This case report describes a 23-year-old Asian woman with fluoxetine non-responsive trichotillomania who showed significant improvement with bupropion and cognitive behavior therapy, though confirmation in larger trials is needed.

This study found that Epristeride and Finasteride reduced prostate development and testis weight in male rats, but only Finasteride appeared to impact reproductive function.

This study found that eflornithine 15% cream reduced unwanted facial hair growth more effectively than a placebo in women with hirsutism, but hair growth returned to pretreatment levels within 8 weeks of stopping treatment.

This study found that the antidepressant-like effect of fluoxetine in mice was only observed when a 5-minute pretest session was conducted, and this effect was blocked by the TSPO antagonist PK11195.

This case report from the University of Alabama, Birmingham describes a rare paradoxical reaction of increased agitation and hyperactivity in a patient with schizoaffective disorder treated with divalproex sodium.

This article reviews the prescription-only cream eflornithine for managing facial hirsutism in women and reports no new clinical results; the authors evaluate its potential role in treatment.

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.